title: New treatments highlighted for lymphoma and multiple myeloma.
authors.forename: Carrie
authors.initials: C
authors.lastname: Printz
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data*; D017326:Clinical Trials, Phase III as Topic; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D009842:Oligopeptides / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D009842:Oligopeptides; D013792:Thalidomide; C524865:carfilzomib; D003907:Dexamethasone; D000079963:Brentuximab Vedotin; D000077269:Lenalidomide